OptimizeRx (NASDAQ:OPRX – Get Free Report) and OneMedNet (NASDAQ:ONMD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
Insider and Institutional Ownership
76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 0.9% of OneMedNet shares are held by institutional investors. 7.5% of OptimizeRx shares are held by insiders. Comparatively, 50.2% of OneMedNet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares OptimizeRx and OneMedNet”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OptimizeRx | $109.43 million | 1.38 | $5.13 million | $0.23 | 34.96 |
| OneMedNet | $1.36 million | 24.76 | -$2.80 million | ($0.16) | -3.55 |
OptimizeRx has higher revenue and earnings than OneMedNet. OneMedNet is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
OptimizeRx has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, OneMedNet has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Profitability
This table compares OptimizeRx and OneMedNet’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OptimizeRx | 4.66% | 9.44% | 7.11% |
| OneMedNet | -584.20% | N/A | -521.20% |
Analyst Ratings
This is a summary of recent ratings for OptimizeRx and OneMedNet, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OptimizeRx | 1 | 2 | 6 | 0 | 2.56 |
| OneMedNet | 1 | 0 | 0 | 0 | 1.00 |
OptimizeRx currently has a consensus price target of $11.43, indicating a potential upside of 42.15%. Given OptimizeRx’s stronger consensus rating and higher possible upside, equities analysts clearly believe OptimizeRx is more favorable than OneMedNet.
Summary
OptimizeRx beats OneMedNet on 11 of the 14 factors compared between the two stocks.
About OptimizeRx
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
About OneMedNet
OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet Corporation is based in Eden Prairie, Minnesota.
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
